MUMBAI, June 12, 2007--Intas Biopharmaceuticals Limited (IBPL) has achieved a unique distinction to become India’s first dedicated biopharmaceutical company to receive certification of European Agency for the Evaluation of Medicinal Products (EMEA) or an EU-GMP certification for its manufacturing facility at Ahmedabad, Gujarat. The certification is a significant step towards fulfilment of IBPL’s plans to tap Europe market. Moreover the certification give strong advantage to IBPL as the company can strengthen existing alliances and look forward to possible agreements with other pharma/biotech companies in new geographical regions of Europe.
